Edition:
United States

Nektar Therapeutics (NKTR.O)

NKTR.O on Nasdaq

35.17USD
18 Jun 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$35.17
Open
$33.80
Day's High
$35.43
Day's Low
$33.80
Volume
1,211,468
Avg. Vol
1,663,674
52-wk High
$69.76
52-wk Low
$29.22

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 2.74
Market Cap(Mil.): $5,874.15
Shares Outstanding(Mil.): 174.31
Dividend: --
Yield (%): --

Financials

  NKTR.O Industry Sector
P/E (TTM): 9.56 103.73 36.81
EPS (TTM): 3.52 -- --
ROI: 53.05 7.70 12.05
ROE: 77.86 8.20 16.96

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

Feb 15 2019

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Feb 15 Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

Feb 15 2019

Earnings vs. Estimates